BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24492834)

  • 1. Bilateral breast cancers.
    Narod SA
    Nat Rev Clin Oncol; 2014 Mar; 11(3):157-66. PubMed ID: 24492834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
    Narod SA
    Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
    Allué Cabañuz M; Domingo Bretón M; Chóliz Ezquerro J; Arribas Del Amo MD; Güemes Sánchez AT
    Cir Esp (Engl Ed); 2020 Dec; 98(10):612-617. PubMed ID: 32505558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer treatment in mutation carriers: surgical treatment.
    Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
    Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
    Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA;
    Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should the use of contralateral prophylactic mastectomy be increasing as it is?
    Wood WC
    Breast; 2009 Oct; 18 Suppl 3():S93-5. PubMed ID: 19914552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
    Metcalfe K; Gershman S; Ghadirian P; Lynch HT; Snyder C; Tung N; Kim-Sing C; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
    BMJ; 2014 Feb; 348():g226. PubMed ID: 24519767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
    Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
    Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Gershman S; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; McLennan J; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
    Br J Cancer; 2011 Apr; 104(9):1384-92. PubMed ID: 21487411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
    Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
    J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015.
    Kurian AW; Canchola AJ; Ma CS; Clarke CA; Gomez SL
    Cancer; 2020 Mar; 126(5):958-970. PubMed ID: 31750934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Tung N; Armel S; Senter L; Singer CF; Fruscio R; Couch F; Weitzel JN; Karlan B; Foulkes WD; Moller P; Eisen A; Ainsworth P; Neuhausen SL; Olopade O; Sun P; Gronwald J; Narod SA;
    Breast Cancer Res Treat; 2019 Jun; 175(2):443-449. PubMed ID: 30756284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon.
    Angelos P; Bedrosian I; Euhus DM; Herrmann VM; Katz SJ; Pusic A
    Ann Surg Oncol; 2015 Oct; 22(10):3208-12. PubMed ID: 26259752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.